@article{fischer_phthalimide_2025,
	title = {Phthalimide derivatives as a new class of papain‐like protease inhibitors in {SARS}‐{CoV}‐2},
	volume = {358},
	issn = {0365-6233, 1521-4184},
	url = {https://onlinelibrary.wiley.com/doi/10.1002/ardp.202400714},
	doi = {10.1002/ardp.202400714},
	abstract = {Abstract 
             
              The severe acute respiratory syndrome coronavirus 2 ({SARS}‐{CoV}‐2) papain‐like cysteine protease ({PLpro}) represents one of only two essential cysteine proteases involved in the regulation of viral replication. It, therefore, qualifies as a promising therapeutic target for the development of antiviral agents. We identified a previously synthesized protease inhibitor, resulting from an earlier project, as a {PLpro} inhibitor and crafted a structure–activity relationship around the hit, leading to the more potent inhibitors {ZHAWOC}6941 ( 
              17h 
              ) and {ZHAWOC}25153 ( 
              17o 
              ) displaying {IC} 
              50 
              values of 8 and 7 µM, respectively. The two compounds represent a new class of {PLpro} inhibitors and, with single‐digit micromolar {IC} 
              50 
              values, are comparable to inhibitors found in the literature.},
	pages = {e2400714},
	number = {1},
	journaltitle = {Archiv der Pharmazie},
	shortjournal = {Archiv der Pharmazie},
	author = {Fischer, Thomas and Frasson, David and Sievers, Martin and Riedl, Rainer},
	urldate = {2025-06-19},
	date = {2025-01},
	langid = {english},
}